Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
12–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
One or more medical claims with a diagnosis (primary or secondary) of asthma (ICD-9-CM 493.XX) during study period;
One or more outpatient pharmacy claims during the study for one or more of the following "study medications":
Fluticasone propionate/salmeterol xinafoate 250 mcg/50 mcg or 100mcg/50mcg combinations
Fluticasone propionate 110 mcg or 220 mcg
One or more asthma exacerbations (asthma-related hospitalization or emergency department visit, oral corticosteriod prescription drug claim, or a combination of any of the above events) during the 12 months prior to the index date ("pre-index period") or
Five or more prescriptions for a short-acting beta agonist during the pre-index period.
You may not be if
Patients with more than one of the study medications during the 3-month period beginning with the index date;
One or more prescriptions within three months of index date (pre or post) for an ICS or LABA other than the study medications
One or more prescriptions within three months of post index date for:
Any asthma maintenance medication
Any medical claims during study period with a diagnosis of: Chronic obstructive pulmonary disease (COPD) (ICD-9-CM 491, 492, or 496); or Respiratory tract cancer (ICD-9-CM 160-164, or 231)
Clareo Health | Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients
